Quick Answer
Caribou Biosciences, Inc. reported Total Assets of $175.37 million for the year ending 2025.
- Caribou Biosciences, Inc. showed a decrease of -44.0% in Total Assets from 2024 to 2025.
- This data is from Caribou Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $158.40 million | Q3 2021: $461.96 million | Q1 2022: $446.00 million | Q2 2022: $421.37 million | Q3 2022: $398.82 million | Q1 2023: $347.46 million | Q2 2023: $349.65 million | Q3 2023: $457.52 million | Q1 2024: $406.83 million | Q2 2024: $372.94 million | Q3 2024: $344.33 million | Q1 2025: $273.66 million | Q2 2025: $220.90 million | Q3 2025: $194.98 million.
- Over the full 6 years of available data (2020 to 2025), Caribou Biosciences, Inc.'s Total Assets has grown by 386.5%.
- Historical annual values: Fiscal year 2025: $175.37 million | Fiscal year 2024: $313.31 million | Fiscal year 2023: $432.21 million | Fiscal year 2022: $373.77 million | Fiscal year 2021: $442.36 million | Fiscal year 2020: $36.05 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: